(Q41154037)

27 September 2017

1 reference

title

Herpes simplex: evolving concepts (English)

1 reference

27 September 2017

Pereira FA

1

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 October 1996

1 reference

Journal of the American Academy of Dermatology

27 September 2017

published in

1 reference

27 September 2017

volume

35

1 reference

27 September 2017

issue

4

1 reference

27 September 2017

page(s)

503-20; quiz 521-2

1 reference

Molecular biology of herpes simplex virus type 1 latency in the nervous system

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Transcriptional activation by herpes simplex virus type 1 VP16 in vitro and its inhibition by oligopeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Herpes simplex virus virion host shutoff function

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Induced extrusion of DNA from the capsid of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Viral DNA synthesis is required for the efficient expression of specific herpes simplex virus type 1 mRNA species

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Anatomy of Herpes Simplex Virus DNA XII. Accumulation of Head-to-Tail Concatemers in Nuclei of Infected Cells and Their Role in the Generation of the Four Isomeric Arrangements of Viral DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Herpes simplex virus amplicon: cleavage of concatemeric DNA is linked to packaging and involves amplification of the terminally reiterated a sequence.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Latent herpes simplex virus in spinal ganglia of mice

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Recovery of herpes-simplex virus from human trigeminal ganglions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Herpesvirus hominis: isolation from human trigeminal ganglion.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Isolation of Latent Herpes Simplex Virus from the Superior Cervical and Vagus Ganglions of Human Beings

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Isolation of Herpes simplex virus from human trigeminal ganglia, including ganglia from one patient with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Isolation of herpesviruses from trigeminal ganglia of man, monkeys, and cats

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The role of herpes simplex virus type 1 thymidine kinase in pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

GAL4-VP16 is an unusually potent transcriptional activator

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Positive and negative regulation at the herpes simplex virus ICP4 and ICP0 TAATGARAT motifs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Interactions of the Oct-1 POU subdomains with specific DNA sequences and with the HSV alpha-trans-activator protein

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Mechanisms for flexibility in DNA sequence recognition and VP16-induced complex formation by the Oct-1 POU domain

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The octamer binding protein Oct-2 inhibits transactivation of the herpes simplex virus immediate-early genes by the virion protein Vmw65.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The octamer-binding protein Oct-2 represses HSV immediate-early genes in cell lines derived from latently infectable sensory neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Repression of a herpes simplex virus immediate-early promoter by the Oct-2 transcription factor is dependent on an inhibitory region at the N terminus of the protein

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Functional interaction between different isoforms of the Oct-2 transcription factor expressed in neuronal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Inhibition of herpes simplex virus infection by ectopic expression of neuronal splice variants of the Oct-2 transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Activation of the herpes simplex virus immediate-early gene promoters by neuronally expressed POU family transcription factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The opposite and antagonistic effects of the closely related POU family transcription factors Brn-3a and Brn-3b on the activity of a target promoter are dependent on differences in the POU domain

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Viral, neuronal and immune factors which may influence herpes simplex virus (HSV) latency and reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Characterization of nerve growth factor-dependent herpes simplex virus latency in neurons in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Nerve growth factor-dependence of herpes simplex virus latency in peripheral sympathetic and sensory neurons in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The latency-associated transcripts of herpes simplex virus: RNA in search of function

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The HSV-1 2-kb latency-associated transcript is found in the cytoplasm comigrating with ribosomal subunits during productive infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Molecular analysis of herpes simplex virus type 1 during epinephrine-induced reactivation of latently infected rabbits in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Herpes simplex virus latent phase transcription facilitates in vivo reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

An HSV LAT null mutant reactivates slowly from latent infection and makes small plaques on CV-1 monolayers

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

An HSV-1 mutant lacking the LAT TATA element reactivates normally in explant cocultivation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Recurrent Herpes Simplex in the Mouse: Inflammation in the Skin and Activation of Virus in the Ganglia Following Peripheral Stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Prevention of ultraviolet-light-induced herpes labialis by sunscreen

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Inhibition by indomethacin of in vitro reactivation of latent herpes simplex virus type 1 in murine trigeminal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Effect of ibuprofen on the in vitro and in vivo reactivation of latent HSV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Prostaglandins Enhance Spread of Herpes Simplex Virus in Cell Cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The effect of prostaglandins on the multiplication and cell-to-cell spread of herpes simplex virus type 2 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The effect of indomethacin, prostaglandin E2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Effect of indomethacin on ultraviolet radiation-induced recurrent herpes simplex virus disease in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Elevation of cyclic AMP levels in cell lines derived from latently infectable sensory neurons increases their permissivity for herpes virus infection by activating the viral immediate-early 1 gene promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Cell-type-specific induction of the UL9 gene of HSV-1 by cell signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

In vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The roles of the cAMP-response element and TATA box in expression of the herpes simplex virus type 1 latency-associated transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Activation of second-messenger pathways reactivates latent herpes simplex virus in neuronal cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The role of cyclic nucleotide mediators in latency and reactivation of HSV-1 infected neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Prevalence and correlates of herpes simplex infections. The population-based AIDS in Multiethnic Neighborhoods Study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Identification of Women at Unsuspected Risk of Primary Infection with Herpes Simplex Virus Type 2 during Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Risk Factors for the Sexual Transmission of Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Herpes simplex virus infections during the decade since the licensure of acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Inability of Enzyme Immunoassays to Discriminate between Infections with Herpes Simplex Virus Types 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Transmission of genital herpes by donor insemination

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Prior herpes simplex virus type 2 infection as a risk factor for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

High prevalence of herpes simplex virus type 1 in female anogenital herpes simplex in Newcastle upon Tyne 1983-92.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Rapid detection and distinction of cutaneous herpesvirus infections by direct immunofluorescence

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1983 and 1989: implications for STD epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Sexually transmitted diseases in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Preventing Neonatal Herpes — Current Strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Recurrence rates in genital herpes after symptomatic first-episode infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Virologic characteristics of subclinical and symptomatic genital herpes infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Acyclovir: A Decade Later

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Antiviral agents in dermatology: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Double-blind Placebo-Controlled Trial of Oral Acyclovir in First-Episode Genital Herpes Simplex Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Pharmacokinetics of acyclovir after intravenous and oral administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Safety of famciclovir in patients with herpes zoster and genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Mechanism of action of foscarnet against viral polymerases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Antivirals for the treatment of herpesvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

A New Topical Treatment for Resistant Herpes Simplex Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Herpes simplex virus vaccines as immunotherapeutic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Efficacy of herpes vaccine and acyclovir (ACV) in a rabbit model following intraocular inoculation of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

HIV and sexually transmitted diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Adenovirus vectors as potential vaccines against herpes simplex virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

DNA immunization against experimental genital herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990670-2

7 January 2021

10.1016/S0190-9622(96)90670-2

Identifiers

DOI

1 reference

27 September 2017

1 reference